Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, et al.
EBioMedicine (2022) Vol. 84, pp. 104270-104270
Open Access | Times Cited: 138

Showing 26-50 of 138 citing articles:

An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters
Shaofeng Deng, Ying Liu, Rachel Chun-Yee Tam, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 28
Evolution of the SARS-CoV-2 Omicron spike
Ruth Parsons, Priyamvada Acharya
Cell Reports (2023) Vol. 42, Iss. 12, pp. 113444-113444
Open Access | Times Cited: 28
SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids
Romal Stewart, Kexin Yan, Sevannah A. Ellis, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 22
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection
Chansavath Phetsouphanh, Brendan Jacka, Sara Ballouz, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
Daniele Focosi, Massimo Franchini, Arturo Casadevall, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 999-1006
Closed Access | Times Cited: 12
Antibody titers and breakthrough infections with Omicron SARS-CoV-2
Chloé Dimeglio, Marion Migueres, Jean‐Michel Mansuy, et al.
Journal of Infection (2022) Vol. 84, Iss. 4, pp. e13-e15
Open Access | Times Cited: 35
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations
Henning Jacobsen, Monika Strengert, Henrike Maaß, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 35
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra, Elitza S. Theel
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 30
Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection
Endeshaw Chekol Abebe, Markeshaw Tiruneh G Medhin, Awgichew Behaile T Mariam, et al.
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 1871-1887
Open Access | Times Cited: 30
Intrinsic furin-mediated cleavability of the spike S1/S2 site from SARS-CoV-2 variant B.1.1.529 (Omicron)
Bailey Lubinski, Javier A. Jaimes, Gary R. Whittaker
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 30
“Is Omicron mild”? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies
Vijay Rani Rajpal, Shashi Sharma, Avinash Kumar, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 8, pp. 3521-3539
Open Access | Times Cited: 29
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Yandong Shen, Jane A. Freeman, Juliette Holland, et al.
Blood (2022) Vol. 140, Iss. 25, pp. 2709-2721
Open Access | Times Cited: 29
A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts
Joseph Chen, Jessica A. Neil, Jianping Tan, et al.
Nature Cell Biology (2023) Vol. 25, Iss. 8, pp. 1223-1234
Open Access | Times Cited: 19
HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment
Dimitris Basoulis, Elpida Mastrogianni, Pantazis-Michail Voutsinas, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 577-577
Open Access | Times Cited: 18
Immunogenicity, effectiveness and safety of SARS-CoV-2 vaccination in people living with HIV: A systematic review and meta-analysis
David Griffin, Rekha Pai Mangalore, Jennifer Hoy, et al.
AIDS (2023)
Open Access | Times Cited: 16
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 16
Spherical neutralizing aptamer suppresses SARS-CoV-2 Omicron escape
Miao Sun, Zijing Wu, Jialü Zhang, et al.
Nano Today (2022) Vol. 44, pp. 101499-101499
Open Access | Times Cited: 26
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
Laura Matrajt, Elizabeth R. Brown, Myron S. Cohen, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Ellen Bowden-Reid, Scott Ledger, Yuan Zhang, et al.
Antiviral Research (2023) Vol. 217, pp. 105677-105677
Open Access | Times Cited: 14
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19—VISION Network, 10 States, June 2021–March 2023
Eric P. Griggs, Patrick K. Mitchell, Victoria Lazariu, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 2, pp. 338-348
Open Access | Times Cited: 13
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy
María Stefania Infante, David Nemirovsky, Sean M. Devlin, et al.
Transplantation and Cellular Therapy (2023) Vol. 30, Iss. 1, pp. 116.e1-116.e12
Open Access | Times Cited: 12
A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2
Weiqi Wang, Shen Wang, Xianyong Meng, et al.
Antiviral Research (2024) Vol. 225, pp. 105854-105854
Closed Access | Times Cited: 4
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100811-100811
Open Access | Times Cited: 19

Scroll to top